看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' m/ o( y4 x& S5 y! @$ b" _6 o6 o+ u4 \/ b, p- Z% j, W! w( l# G
% i6 N5 V0 h# V: UCurrently available feasibility data for possible combination strategies. 1 m- p4 c2 \- S
————————————————————————————————& l, F7 Q5 o+ l+ _5 n" \
Combination Feasibility according to preliminary data
: L1 ]$ B7 O' F! G" \. J3 i——————————————————————————————————
; F. P! }9 t; }" J; m I4 P3 q8 HBevacizumab + sorafenib Yes, reduced dose . a7 s$ M& ? W! T" c% U- r
Bevacizumab + sunitinib† No
% I+ B+ g( P) f( ?) w5 a uBevacizumab + temsirolimus Yes 5 a' U6 u1 ~7 K# U
Bevacizumab + everolimus Yes
5 c$ y. [9 r5 rSorafenib + sunitinib ?
; B5 v( Q2 R, M V7 g; d' M' C, ASorafenib + temsirolimus Yes, reduced dose
+ u! ^, H' Y: m( Q7 oSorafenib + everolimus Yes, reduced dose 0 Z* R0 t) \1 U! y) A
Sunitinib + temsirolimus† No - T" Z0 I' f# [; \% K: a0 k7 I7 E! [
Sunitinib + everolimus ? & b: M. N5 V* y4 h6 R2 _ M
Temsirolimus + everolimus ? 8 z. S% J- y. _' S! a
————————————————————. O5 D7 T6 I* v( @, | ?
†Led to US FDA warning.5 v# @$ x" r: K% m
?: As yet unattempted combination.* B i4 D$ v, r; W1 f% T+ G7 q
|